Evidence is piling up to support the idea that the Food and Drug Administration — under President Trump and new Commissioner Scott Gottlieb — is lowering the regulatory bar for drug approvals. It would be foolish to draw definitive conclusions at this point, but it sure looks to me as though the agency’s relationship with the drug industry is cozy these days.

What does that mean for investors — and patients ? Let’s walk through it.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • The public will remain guinea pigs with respect to learning the safety profile of what they are being prescribed and putting in their bodies. The difference is now that the risks may be more frequent or severe and the benefit for which they are taking those risks now also will be uncertain.

  • Bias much? New guy, Adam Feurstein’s hatred of all things Trump is well known on twitter as he posted his need for a safe space last November. I’m sure everyone at Stat is as bias and anti-Trump as Adam is. Just looking through the headlines tells everyone you’re BIAS & political.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy